Study suggests experimental drug dismantles 2 key proteins that help tumors survive, adapt and resist treatment

Scientists from Roswell Park Comprehensive Cancer Center study that the investigational anticancer cause FL118 functions arsenic a dual molecular glue degrader that straight targets and degrades the proteins DDX5 and UbE2T, 2 emerging therapeutic targets linked to crab endurance mechanisms.